A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PHASE I SAFETY AND IMMUNOGENICITY TRIAL OF RECOMBINANT ENVELOPE PROTEIN, HIV-1 SF-2 RGP120 (BIOCINE), COMBINED WITH MF59 IN HIV-1 UNINFECTED ADULT VOLUNTEERS: